Sunday , September 22 2019
Home / mexico / New female viagra for premenopausal women approved in EU | TRIBUNA

New female viagra for premenopausal women approved in EU | TRIBUNA



Washington, Recently, marketing of a new treatment for women suffering from loss of sexual desire has been approved by the Food and Drug Administration of the United States (FDA).

O Vyleesi (bremelanotide), indicated to be injected at least 45 minutes before sexual activity, received approval to treat the sexual desire Hypothesis Generalized Acquired (HSDD) in premenopausal women, the FDA said in a statement.

The drug, according to the US agency, "activates melanocortin receptors," although "the mechanism by which it improves sexual desire and related suffering" is unknown.

Among the side effects, the FDA mentioned nausea, vomiting, flushing, injection site reactions and headache.

Vyleesi, which will be distributed by AMAG Pharmaceuticals, caused an increase in blood pressure after its application that was resolved in 12 hours, the authority explained, commenting on the results of clinical trials.

In that context, he warned that because of this effect, the drug "should not be used in patients with uncontrolled high blood pressure or in patients with known cardiovascular disease."

He also warned that this drug may significantly reduce the levels of oral naltrexone used in patients with alcohol or opioid dependence, which may lead to treatment failure.

In August 2015, the FDA authorized the pharmaceutical company Sprout Pharmaceuticals to place the flibanserin on sale since October of the same year under the brand Addyi.

The drug is to be given daily to premenopausal women who suffer from a sexual anorexia disorder, that is, the sudden loss of any desire to have sex.

Addyi's approval was not as well received in the scientific community as among feminist collectives, as numerous doctors and pharmacologists questioned at the time not only the effects of the medication but the very nature of the alleged sexual disorder.

This note includes information on:
EFE

Themes

Source link